{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:41:08Z","timestamp":1794674468639,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000146","name":"NSF | ENG\/OAD | Division of Chemical, Bioengineering, Environmental, and Transport Systems","doi-asserted-by":"publisher","award":["2103219"],"award-info":[{"award-number":["2103219"]}],"id":[{"id":"10.13039\/100000146","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM133646"],"award-info":[{"award-number":["R35GM133646"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CRI4018"],"award-info":[{"award-number":["CRI4018"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6580-20"],"award-info":[{"award-number":["6580-20"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1K22CA258520-01"],"award-info":[{"award-number":["1K22CA258520-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA252239"],"award-info":[{"award-number":["R01CA252239"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228135"],"award-info":[{"award-number":["R01CA228135"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA242020"],"award-info":[{"award-number":["R01CA242020"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["O1CA266212"],"award-info":[{"award-number":["O1CA266212"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"publisher","award":["222549"],"award-info":[{"award-number":["222549"]}],"id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009741","name":"AABB | National Blood Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-20-1-0417"],"award-info":[{"award-number":["W81XWH-20-1-0417"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell immunotherapy is promising for treatment of blood cancers; however, clinical benefits remain unpredictable, necessitating development of optimal CAR T cell products. Unfortunately, current preclinical evaluation platforms are inadequate owing to their limited physiological relevance to humans. Here we engineer an organotypic immunocompetent chip that recapitulates microarchitectural and pathophysiological characteristics of human leukaemia bone marrow stromal and immune niches for CAR T cell therapy modelling. This leukaemia chip empowers real-time spatiotemporal monitoring of CAR T cell functionality, including T cell extravasation, recognition of leukaemia, immune activation, cytotoxicity and killing. We use our chip to model clinically observed heterogeneous responses such as remission, resistance and relapse under CAR T cell therapy and map factors that drive therapeutic success or failure. Finally, we demarcate functional performance of CAR T cells produced from different healthy donors and patients with cancer, with various CAR designs and protocols, systematically and multidimensionally. Together, our chip introduces an enabling \u2018(pre-)clinical-trial-on-chip\u2019 tool for CAR T cell development, which may translate to personalized therapies and improved clinical decision-making.<\/jats:p>","DOI":"10.1038\/s41551-025-01428-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:02:51Z","timestamp":1751346171000},"page":"2098-2114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1023-1326","authenticated-orcid":false,"given":"Chao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5966-1721","authenticated-orcid":false,"given":"Huishu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandana","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadab","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Witkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iannis","family":"Aifantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-3576","authenticated-orcid":false,"given":"Saba","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-8328","authenticated-orcid":false,"given":"Weiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1428_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1428_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"1428_CR3","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1428_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1428_CR5","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1428_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1428_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"1428_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1428_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"1428_CR10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"1428_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","volume":"5","author":"J Wei","year":"2020","unstructured":"Wei, J. et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct. Target. Ther. 5, 134 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1428_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"1428_CR13","doi-asserted-by":"publisher","unstructured":"Jazirehi, A. R. et al. Clinical implications of anti-CD19 chimeric antigen receptors (CAR) T cell therapy in acute lymphoblastic leukemia (ALL). Immunotherapy: Open Access https:\/\/doi.org\/10.4172\/2471-9552.1000142 (2017).","DOI":"10.4172\/2471-9552.1000142"},{"key":"1428_CR14","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht, J. et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget 7, 76902\u201376919 (2016).","journal-title":"Oncotarget"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"1428_CR16","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella, M. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814\u20133826 (2016).","journal-title":"J. Clin. Invest."},{"key":"1428_CR17","doi-asserted-by":"publisher","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","volume":"11","author":"H Qin","year":"2019","unstructured":"Qin, H. et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci. Transl. Med. 11, eaaw9414 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1428_CR18","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"1428_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016).","journal-title":"Nat. Commun."},{"key":"1428_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov."},{"key":"1428_CR21","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3390\/ijms23063154","volume":"23","author":"X Si","year":"2022","unstructured":"Si, X. et al. Preclinical evaluation of CAR T cell function: in vitro and in vivo models. Int. J. Mol. Sci. 23, 3154 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1428_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1089\/hum.2017.243","volume":"29","author":"EL Siegler","year":"2018","unstructured":"Siegler, E. L. & Wang, P. Preclinical models in chimeric antigen receptor-engineered T-cell therapy. Hum. Gene Ther. 29, 534\u2013546 (2018).","journal-title":"Hum. Gene Ther."},{"key":"1428_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","volume":"16","author":"S Kiesgen","year":"2021","unstructured":"Kiesgen, S. et al. Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nat. Protoc. 16, 1331\u20131342 (2021).","journal-title":"Nat. Protoc."},{"key":"1428_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day, C. P. et al. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163, 39\u201353 (2015).","journal-title":"Cell"},{"key":"1428_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nbt.2989","volume":"32","author":"SN Bhatia","year":"2014","unstructured":"Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760\u2013772 (2014).","journal-title":"Nat. Biotechnol."},{"key":"1428_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","volume":"24","author":"F Weeber","year":"2017","unstructured":"Weeber, F. et al. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem. Biol. 24, 1092\u20131100 (2017).","journal-title":"Cell Chem. Biol."},{"key":"1428_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","volume":"23","author":"DE Ingber","year":"2022","unstructured":"Ingber, D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat. Rev. Genet. 23, 467\u2013491 (2022).","journal-title":"Nat. Rev. Genet."},{"key":"1428_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ccell.2020.04.015","volume":"37","author":"MT Witkowski","year":"2020","unstructured":"Witkowski, M. T. et al. Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia. Cancer Cell 37, 867\u2013882.e12 (2020).","journal-title":"Cancer Cell"},{"key":"1428_CR29","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41590-022-01314-y","volume":"23","author":"MT Witkowski","year":"2022","unstructured":"Witkowski, M. T. et al. NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nat. Immunol. 23, 1424\u20131432 (2022).","journal-title":"Nat. Immunol."},{"key":"1428_CR30","doi-asserted-by":"publisher","first-page":"eaba5536","DOI":"10.1126\/sciadv.aba5536","volume":"6","author":"C Ma","year":"2020","unstructured":"Ma, C. et al. Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche. Sci. Adv. 6, eaba5536 (2020).","journal-title":"Sci. Adv."},{"key":"1428_CR31","doi-asserted-by":"publisher","first-page":"9342","DOI":"10.1073\/pnas.1201240109","volume":"109","author":"Y Zheng","year":"2012","unstructured":"Zheng, Y. et al. In vitro microvessels for the study of angiogenesis and thrombosis. Proc. Natl Acad. Sci. USA 109, 9342\u20139347 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1428_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1039\/c3lc41320a","volume":"13","author":"S Kim","year":"2013","unstructured":"Kim, S. et al. Engineering of functional, perfusable 3D microvascular networks on a chip. Lab Chip 13, 1489\u20131500 (2013).","journal-title":"Lab Chip"},{"key":"1428_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1073\/pnas.1417115112","volume":"112","author":"JS Jeon","year":"2015","unstructured":"Jeon, J. S. et al. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc. Natl Acad. Sci. USA 112, 214\u2013219 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1428_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans, C. et al. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15, 786\u2013801 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1428_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J. et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"1428_CR36","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1161\/01.RES.0000191547.64391.e3","volume":"97","author":"GE Davis","year":"2005","unstructured":"Davis, G. E. & Senger, D. R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97, 1093\u20131107 (2005).","journal-title":"Circ. Res."},{"key":"1428_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41586-019-1104-8","volume":"569","author":"AN Tikhonova","year":"2019","unstructured":"Tikhonova, A. N. et al. The bone marrow microenvironment at single-cell resolution. Nature 569, 222\u2013228 (2019).","journal-title":"Nature"},{"key":"1428_CR38","doi-asserted-by":"publisher","first-page":"e124928","DOI":"10.1172\/jci.insight.124928","volume":"3","author":"KA Oetjen","year":"2018","unstructured":"Oetjen, K. A. et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight 3, e124928 (2018).","journal-title":"JCI Insight"},{"key":"1428_CR39","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cell.2019.04.040","volume":"177","author":"N Baryawno","year":"2019","unstructured":"Baryawno, N. et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177, 1915\u20131932.e16 (2019).","journal-title":"Cell"},{"key":"1428_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41556-019-0439-6","volume":"22","author":"C Baccin","year":"2020","unstructured":"Baccin, C. et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat. Cell Biol. 22, 38\u201348 (2020).","journal-title":"Nat. Cell Biol."},{"key":"1428_CR41","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood-2008-02-142430","volume":"112","author":"J Kirshner","year":"2008","unstructured":"Kirshner, J. et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112, 2935\u20132945 (2008).","journal-title":"Blood"},{"key":"1428_CR42","doi-asserted-by":"publisher","first-page":"e134612","DOI":"10.1172\/jci.insight.134612","volume":"5","author":"PH Chen","year":"2020","unstructured":"Chen, P. H. et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 5, e134612 (2020).","journal-title":"JCI Insight"},{"key":"1428_CR43","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/leu.2014.108","volume":"28","author":"MH Andersen","year":"2014","unstructured":"Andersen, M. H. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 28, 1784\u20131792 (2014).","journal-title":"Leukemia"},{"key":"1428_CR44","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"1428_CR45","first-page":"1","volume":"51","author":"M Jin","year":"2019","unstructured":"Jin, M. Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications. Exp. Mol. Med. 51, 1\u201310 (2019).","journal-title":"Exp. Mol. Med."},{"key":"1428_CR46","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1182\/blood.2021012328","volume":"139","author":"S Buchmann","year":"2022","unstructured":"Buchmann, S. et al. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood 139, 1785\u20131793 (2022).","journal-title":"Blood"},{"key":"1428_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","volume":"10","author":"CS Hourigan","year":"2013","unstructured":"Hourigan, C. S. & Karp, J. E. Minimal residual disease in acute myeloid leukaemia. Nat. Rev. Clin. Oncol. 10, 460\u2013471 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1428_CR48","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJ van Dongen","year":"2015","unstructured":"van Dongen, J. J. et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125, 3996\u20134009 (2015).","journal-title":"Blood"},{"key":"1428_CR49","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis, G. J. et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131, 1275\u20131291 (2018).","journal-title":"Blood"},{"key":"1428_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005360","volume":"10","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. J. Immunother. Cancer 10, e005360 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1428_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","journal-title":"Sci. Adv."},{"key":"1428_CR52","doi-asserted-by":"publisher","first-page":"e00232","DOI":"10.1136\/jitc-2020-002328","volume":"9","author":"Z Bai","year":"2021","unstructured":"Bai, Z. et al. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. J. Immunother. Cancer 9, e00232 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1428_CR53","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"1428_CR54","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100\u20131109 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1428_CR55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi, S. et al. Rapid manufacturing of non-activated potent CAR T cells. Nat. Biomed. Eng. 6, 118\u2013128 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1428_CR56","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"1428_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103241","volume":"9","author":"G Goyal","year":"2022","unstructured":"Goyal, G. et al. Ectopic lymphoid follicle formation and human seasonal influenza vaccination responses recapitulated in an organ-on-a-chip. Adv. Sci. 9, e2103241 (2022).","journal-title":"Adv. Sci."},{"key":"1428_CR58","doi-asserted-by":"publisher","first-page":"e89762","DOI":"10.1172\/jci.insight.89762","volume":"2","author":"A Pavesi","year":"2017","unstructured":"Pavesi, A. et al. A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors. JCI Insight 2, e89762 (2017).","journal-title":"JCI Insight"},{"key":"1428_CR59","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fimmu.2018.00416","volume":"9","author":"SWL Lee","year":"2018","unstructured":"Lee, S. W. L. et al. Characterizing the role of monocytes in T cell cancer immunotherapy using a 3D microfluidic model. Front. Immunol. 9, 416 (2018).","journal-title":"Front. Immunol."},{"key":"1428_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201901829","volume":"6","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Dynamic profiling of antitumor activity of CAR T cells using micropatterned tumor arrays. Adv. Sci. 6, 1901829 (2019).","journal-title":"Adv. Sci."},{"key":"1428_CR61","doi-asserted-by":"publisher","first-page":"e126345","DOI":"10.1172\/jci.insight.126345","volume":"4","author":"L Wallstabe","year":"2019","unstructured":"Wallstabe, L. et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight 4, e126345 (2019).","journal-title":"JCI Insight"},{"key":"1428_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201900001","volume":"8","author":"Y Ando","year":"2019","unstructured":"Ando, Y. et al. Evaluating CAR-T cell therapy in a hypoxic 3D tumor model. Adv. Healthc. Mater. 8, e1900001 (2019).","journal-title":"Adv. Healthc. Mater."},{"key":"1428_CR63","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3389\/fimmu.2019.01133","volume":"10","author":"D Park","year":"2019","unstructured":"Park, D. et al. High-throughput microfluidic 3D cytotoxicity assay for cancer immunotherapy (CACI-IMPACT platform). Front. Immunol. 10, 1133 (2019).","journal-title":"Front. Immunol."},{"key":"1428_CR64","doi-asserted-by":"publisher","first-page":"1553477","DOI":"10.1080\/2162402X.2018.1553477","volume":"8","author":"JM Ayuso","year":"2019","unstructured":"Ayuso, J. M. et al. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology 8, 1553477 (2019).","journal-title":"Oncoimmunology"},{"key":"1428_CR65","doi-asserted-by":"publisher","first-page":"eabc2331","DOI":"10.1126\/sciadv.abc2331","volume":"7","author":"JM Ayuso","year":"2021","unstructured":"Ayuso, J. M. et al. Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion. Sci. Adv. 7, eabc2331 (2021).","journal-title":"Sci. Adv."},{"key":"1428_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202004282","volume":"17","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. Cancer-on-a-chip for modeling immune checkpoint inhibitor and tumor interactions. Small 17, e2004282 (2021).","journal-title":"Small"},{"key":"1428_CR67","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","volume":"8","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W. et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 8, 196\u2013215 (2018).","journal-title":"Cancer Discov."},{"key":"1428_CR68","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.7150\/thno.71761","volume":"12","author":"Z Ao","year":"2022","unstructured":"Ao, Z. et al. Evaluation of cancer immunotherapy using mini-tumor chips. Theranostics 12, 3628\u20133636 (2022).","journal-title":"Theranostics"},{"key":"1428_CR69","doi-asserted-by":"publisher","first-page":"e67106","DOI":"10.7554\/eLife.67106","volume":"10","author":"SJ Kerns","year":"2021","unstructured":"Kerns, S. J. et al. Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. eLife 10, e67106 (2021).","journal-title":"eLife"},{"key":"1428_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123016","volume":"316","author":"D Ghoshal","year":"2024","unstructured":"Ghoshal, D. et al. Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myeloma. Biomaterials 316, 123016 (2024).","journal-title":"Biomaterials"},{"key":"1428_CR71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249\u2013258 (2017).","journal-title":"Mol. Ther."},{"key":"1428_CR72","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","volume":"7","author":"M Ruella","year":"2017","unstructured":"Ruella, M. et al. Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells. Cancer Discov. 7, 1154\u20131167 (2017).","journal-title":"Cancer Discov."},{"key":"1428_CR73","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1158\/2643-3230.BCD-22-0067","volume":"3","author":"U Uslu","year":"2022","unstructured":"Uslu, U. & June, C. H. CAR T-cell therapy meets clonal hematopoiesis. Blood Cancer Discov. 3, 382\u2013384 (2022).","journal-title":"Blood Cancer Discov."},{"key":"1428_CR74","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","volume":"5","author":"PG Miller","year":"2021","unstructured":"Miller, P. G. et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 5, 2982\u20132986 (2021).","journal-title":"Blood Adv."},{"key":"1428_CR75","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","volume":"6","author":"R Teipel","year":"2022","unstructured":"Teipel, R. et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 6, 1941\u20131946 (2022).","journal-title":"Blood Adv."},{"key":"1428_CR76","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","volume":"561","author":"H Lee-Six","year":"2018","unstructured":"Lee-Six, H. et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 561, 473\u2013478 (2018).","journal-title":"Nature"},{"key":"1428_CR77","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","volume":"586","author":"AG Bick","year":"2020","unstructured":"Bick, A. G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature 586, 763\u2013768 (2020).","journal-title":"Nature"},{"key":"1428_CR78","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","volume":"606","author":"MA Fabre","year":"2022","unstructured":"Fabre, M. A. et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 606, 335\u2013342 (2022).","journal-title":"Nature"},{"key":"1428_CR79","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/2159-8290.CD-22-0199","volume":"13","author":"AO Khan","year":"2023","unstructured":"Khan, A. O. et al. Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies. Cancer Discov. 13, 364\u2013385 (2023).","journal-title":"Cancer Discov."},{"key":"1428_CR80","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41592-024-02172-2","volume":"21","author":"S Frenz-Wiessner","year":"2024","unstructured":"Frenz-Wiessner, S. et al. Generation of complex bone marrow organoids from human induced pluripotent stem cells. Nat. Methods 21, 868\u2013881 (2024).","journal-title":"Nat. Methods"},{"key":"1428_CR81","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A. et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1428_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2019","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1428_CR83","unstructured":"Ma, C. et al. A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immuno-therapy. Gene Expression Omnibus https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE293390 (2025)."},{"key":"1428_CR84","doi-asserted-by":"crossref","unstructured":"Waltman, L. & van Eck, N. J. A smart local moving algorithm for large-scale modularity-based community detection. Eur. Phys. J. B 86, 471 (2013).","DOI":"10.1140\/epjb\/e2013-40829-0"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01428-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:03:22Z","timestamp":1781172202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01428-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":84,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01428-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2762929\/v1","asserted-by":"object"}]},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.A. is a consultant for Foresite Labs. M.T.W. has received royalties from the Walter and Eliza Hall Institute for the development of venetoclax unrelated to the current paper. C.M. and W.C. are inventors (New York University) on a patent (20240198337) for bone marrow on a chip technology and a patent (20230032623) for tumour-on-a-chip technology. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}